Chemkart India promoter group member increases stake to 0.04%

1 min read     Updated on 09 Jul 2026, 11:27 AM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Promoter group member Jaini Shailesh Mehta increased her stake in Chemkart India Ltd by acquiring 1,200 equity shares on July 6, 2026. The transaction, conducted on the BSE Limited, raised her total holding to 5,407 shares or 0.04% of the paid-up equity share capital. The disclosure was made in compliance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

powered bylight_fuzz_icon
43934830

*this image is generated using AI for illustrative purposes only.

Promoter group member Jaini Shailesh Mehta has increased her shareholding in Chemkart India Ltd by acquiring 1,200 equity shares through an open market transaction on BSE Limited. The acquisition, executed on July 6, 2026, raised her total stake to 0.04% of the paid-up equity share capital. The disclosure was submitted to the exchange in compliance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Prior to the transaction, Jaini Shailesh Mehta held 4,207 shares, accounting for a 0.03% stake. Following the purchase of 1,200 shares, her total holding stands at 5,407 shares. The company's total paid-up equity share capital is ₹12,09,90,000, divided into 1,20,99,000 equity shares of ₹10 each. The intimation regarding this acquisition was submitted to the company and the stock exchange on July 8, 2026.

Shareholding Details

Description Jaini Shailesh Mehta
Category Promoter Group
Securities Acquired 1,200 Equity Shares
Pre-acquisition Holding 4,207 shares (0.03%)
Post-acquisition Holding 5,407 shares (0.04%)
Date of Acquisition July 6, 2026
Date of Intimation July 8, 2026
Mode of Acquisition Open Market
Exchange BSE Limited

Historical Stock Returns for Chemkart

1 Day5 Days1 Month6 Months1 Year5 Years
-4.31%-8.33%+28.57%+69.97%-26.50%-30.62%

Does this acquisition signal a broader trend of increased promoter confidence in Chemkart India's future performance?

Could this move be a precursor to further stake accumulation by other promoter group members in the near term?

How might the market interpret this insider purchase in light of the company's recent financial results?

Chemkart invests ₹10 lakh in subsidiary Vinstar Biotech

1 min read     Updated on 20 Jun 2026, 04:50 PM
scanx
Reviewed by
Suketu GScanX News Team
AI Summary

Chemkart India invested ₹10 lakh in its wholly-owned subsidiary Vinstar Biotech via a rights issue to fund capital and working capital needs. The subsidiary, an R&D-driven nutraceutical firm, reported a turnover of ₹223.43 Lakhs for FY26 but remained loss-making.

powered bylight_fuzz_icon
43500040

*this image is generated using AI for illustrative purposes only.

Chemkart India has invested ₹10 lakh in its wholly-owned subsidiary, Vinstar Biotech Private Limited, through a rights issue. The investment was made to support the subsidiary's capital expenditure and working capital requirements.

The company allotted 1,00,000 equity shares with a face value of ₹10 each at an issue price of ₹10 per share. Following this allotment, Chemkart India continues to hold 100% of the shareholding in Vinstar Biotech. The transaction was conducted at arm's length and falls under the ambit of related party transactions.

Vinstar Biotech is an R&D-driven nutraceutical company incorporated in 2023. It specializes in proprietary bioactive technologies and the commercial distribution of health and nutraceutical products. The entity focuses on liposomal and microencapsulated delivery platforms to enhance the bioavailability of health supplements, vitamins, and amino acids.

As of March 31, 2026, Vinstar Biotech reported a turnover of ₹223.43 Lakhs. The entity recorded a loss after tax of ₹24.72 Lakhs and a net worth of negative ₹34.69 Lakhs. The subsidiary had no turnover in the financial years 2023-24 and 2024-25.

Financial Details of Vinstar Biotech

Metric Details
Authorized Share Capital ₹15,00,000 divided into 1,50,000 Equity Shares of ₹10 each
Paid Up Share Capital (Post Allotment) ₹11,00,000 divided into 1,10,000 Equity Shares of ₹10 each
Turnover (as on March 31, 2026) ₹223.43 Lakhs
Loss after Tax (as on March 31, 2026) ₹(24.72) Lakhs
Net Worth (as on March 31, 2026) ₹(34.69) Lakhs

Historical Stock Returns for Chemkart

1 Day5 Days1 Month6 Months1 Year5 Years
-4.31%-8.33%+28.57%+69.97%-26.50%-30.62%

What is the timeline for Vinstar Biotech to achieve profitability given its current negative net worth?

Will Chemkart India need to provide additional capital infusions to sustain Vinstar's operations?

How does Vinstar Biotech plan to scale its proprietary liposomal technology to improve margins?

More News on Chemkart

1 Year Returns:-26.50%